Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-653 in Advanced Solid Tumors and TGCT
NCT05277454Phase 1Unknown
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Jan 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HMPL-653 in advanced malignant solid tumor and tenosynovial giant cell tumor (TGCT), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Occurrence of Dose-Limiting Toxicities up to 33 days, Maximum Tolerated Dose up to 12 months and 1 more. Status: unknown.
02
Drugs
HMPL-653
03
Conditions
advanced malignant solid tumortenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT05277454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277454.